亚太液态切片市场：按最终用户和国家/地区进行的分析和预测（2024-2033 年）

亚太地区液态切片市场规模预计将从 2024 年的 7.081 亿美元增至 2033 年的 29.273 亿美元，预测期内复合年增长率高达 17.08%。

液态切片正在成为亚太地区癌症检测和监测的革命性非侵入性诊断工具。这种新方法创伤性极小，可以提供即时监测以评估治疗反应，并有可能检测早期癌症復发。癌症发病率上升、研究出版物增加以及临床试验增加推动了市场的不断扩大，从而推动了对液态切片测试和产品的需求。对微创诊断技术的偏好导致了更具创新性和更有效率的测试的快速发展。

此外，由于政府采取倡议改善癌症检测和治疗管理，市场正在以更快的速度成长。许多分销管道，包括线上平台和零售店，都生产液态切片产品，确保了整个全部区域的供应和广泛的消费者覆盖范围。这些因素，加上患者对非侵入性癌症筛检日益增长的需求，正在推动亚太液态切片市场的巨大发展势头，全部区域更有效率、更容易获得的癌症检测解决方案铺平道路。

亚太地区液态切片市场作为癌症监测和检测的非侵入性替代方法正在迅速扩张，与传统切片检查技术相比具有许多优势。液态切片检查血液样本中的循环肿瘤DNA（ctDNA）、RNA和外泌体，从而能够早期检测癌症、即时监测和评估治疗效果，同时最大程度地减少患者的不适。由于该地区癌症发生率不断上升，以及对个人化医疗和微创诊断解决方案的需求，这项技术变得越来越受欢迎。

癌症发生率的上升、生物标记检测技术的发展、以及心臟病学和感染疾病等肿瘤学以外的应用的不断扩大是推动市场发展的主要因素。政府措施、研究资金的增加以及优先事项的变化正在促进液态切片在精准医疗中的应用不断扩大。这种日益广泛的应用得益于政府措施、研究经费的增加以及向精准医疗的转变。此外，透过线上平台和医疗保健提供者提供的液态切片测试的日益普及，提高了整个亚太地区的可及性并促进了市场采用，并透过早期诊断和更好的治疗监测改善了患者的治疗效果。

本报告调查了亚太液态切片市场，并总结了主要趋势、影响市场的因素分析、法律制度、技术发展和专利趋势、市场规模和预测的变化、各个细分市场和主要国家的详细分析、竞争格局以及主要企业的概况。

市场区隔:

细分 1：按最终用户

• 学术和研究机构
• 临床实验室
• 製药和生物技术公司
• 企业
• 其他的

细分2：按地区

• 亚太地区
  • 日本
  • 印度
  • 中国
  • 韩国
  • 澳洲
  • 新加坡
  • 其他的

目录

执行摘要

范围和定义

第一章 市场

• 市场趋势
• 供应链分析：亚太液态切片市场
• 法律规范
• COVID-19 对亚太液态切片市场的影响
• 最近推出的产品/服务
• 赎回情况
• 资金筹措方案
• 产品映射分析
• 市场总规模及渗透率
• 液态切片市场：相关利益者分析
• 政府关于液态切片的倡议
• 市场动态概览
  • 市场驱动因素
  • 市场限制
  • 市场机会

第二章 区域

• 亚太地区
  • 区域概况
  • 市场成长推进因素
  • 市场问题
  • 测试次数
  • 市场规模及预测
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 新加坡
  • 其他的

第 3 章市场：竞争基准化分析与公司简介

• 公司简介
  • Sysmex Corporation

第四章调查方法

Introduction to Asia-Pacific Liquid Biopsy Market

The Asia-Pacific liquid biopsy market was valued at $708.1 million in 2024 and is expected to reach $2,927.3 million by 2033, growing at a CAGR of 17.08% during the forecast period 2024-2033. Liquid biopsies are becoming a revolutionary non-invasive diagnostic tool for cancer detection and monitoring in APAC. This novel approach provides real-time monitoring with minimal invasiveness, assesses treatment responses, and has the potential to detect early cancer recurrence detection. There is a greater need for liquid biopsy tests and products as a result of the market's expansion due to the rising prevalence of cancer, rising research publications, and growing clinical trials. More innovative and efficient tests have been developed quickly as a result of the growing preference for minimally invasive diagnostic techniques.

Additionally, the market has grown more quickly as a result of government initiatives that have been implemented to improve cancer detection and treatment management. Many distribution channels, including online platforms and retail outlets, have made liquid biopsy products enhancing accessibility and ensuring broader consumer reach across the region. These factors, along with increasing patient demand for non-invasive cancer screening, are helping the APAC liquid biopsy market gain significant momentum, paving the way for more efficient and accessible cancer detection solutions across the region.

Market Introduction

The APAC Liquid Biopsy Market is expanding quickly as a non-invasive alternative for cancer monitoring and detection, providing a number of benefits over conventional biopsy techniques. With the least amount of discomfort to the patient, liquid biopsy enables early cancer detection, real-time monitoring, and evaluation of treatment responses by examining circulating tumor DNA (ctDNA), RNA, and exosomes from blood samples. Because of the rising incidence of cancer in the area and the need for personalized medicine and minimally invasive diagnostic solutions, this technology is becoming more and more popular.

Rising cancer rates, technological developments in biomarker detection, and the expansion of applications beyond oncology, such as in cardiology and infectious diseases, are the main factors propelling the market's growth. Government initiatives, rising research funding, and a change in priorities are all contributing to the increasing use of liquid biopsy toward precision medicine. The growing adoption of liquid biopsy is supported by government initiatives, increasing research funding, and a shift toward precision medicine. Moreover, the increasing availability of liquid biopsy tests through online platforms and healthcare providers is enhancing accessibility, driving market adoption across APAC, and improving patient outcomes through earlier diagnosis and better treatment monitoring.

Market Segmentation:

Segmentation 1: by End User

• Academic and Research Institutions
• Clinical Laboratories
• Pharmaceutical and Biotechnology
• Companies
• Other End Users

Segmentation 2: by Region

• Asia-Pacific
  • Japan
  • India
  • China
  • South Korea
  • Australia
  • Singapore
  • Rest-of-Asia-Pacific

How can this report add value to an organization?

Product/Innovation Strategy: The Asia-Pacific liquid biopsy market has been segmented based on various categories, such as end user and country.

Competitive Strategy: The Asia-Pacific liquid biopsy market is highly fragmented, with many smaller and private companies constantly entering the market. Key players in the liquid biopsy market analyzed and profiled in the study involve established players that offer various kinds of products and services.

Table of Contents

Executive Summary

Scope and Definition

1 Market

• 1.1 Market Trends
  • 1.1.1 Increasing Product Launches in the Market
  • 1.1.2 Growing Funding by the Key Players in the Market
• 1.2 Supply Chain Analysis: Asia-Pacific Liquid Biopsy Market
• 1.3 Regulatory Framework
  • 1.3.1 Regulation in Other Countries
• 1.4 COVID-19 Impact on Asia-Pacific Liquid Biopsy Market
• 1.5 Recently Launched Product/Services
• 1.6 Reimbursement Scenario
• 1.7 Financing Scenario
  • 1.7.1 Key Players Patent Portfolio
  • 1.7.2 Key Players Stratification as per Raised Financing Value
  • 1.7.3 Key Players Financing Analysis (by Company)
• 1.8 Product Mapping Analysis
  • 1.8.1 By Technology
  • 1.8.2 By Sample
  • 1.8.3 By Circulating Biomarker
  • 1.8.4 By Clinical Application
• 1.9 Total Addressable Market and Penetration
• 1.1 Liquid Biopsy Market: Stakeholder Analysis (N=30)
  • 1.10.1 Physicians' Perception
  • 1.10.2 Payer's Perception
  • 1.10.3 Investors' Perception
• 1.11 Liquid Biopsy Government Initiatives
• 1.12 Market Dynamics Overview
  • 1.12.1 Market Drivers
    • 1.12.1.1 Rising Burden of Cancer
    • 1.12.1.2 Growing Research Publications and Clinical Trials in Liquid Biopsy
    • 1.12.1.3 Growing Adoption and Demand of Minimally Invasive Cancer Detection Methods
  • 1.12.2 Market Restraints
    • 1.12.2.1 Technical Limitations in Liquid Biopsy
    • 1.12.2.2 Uncertain Reimbursement and Recommendations for Liquid Biopsy Tests
  • 1.12.3 Market Opportunities
    • 1.12.3.1 Integration of AI in Liquid Biopsy
    • 1.12.3.2 Use of Liquid Biopsy for Precision Medicine in Oncology

2 Regions

• 2.1 Asia-Pacific
  • 2.1.1 Regional Overview
  • 2.1.2 Driving Factors for Market Growth
  • 2.1.3 Factors Challenging the Market
  • 2.1.4 Test Volume
  • 2.1.5 Market Size and Forecast
    • 2.1.5.1 By End User
  • 2.1.6 China
    • 2.1.6.1 Test Volume
    • 2.1.6.2 Market Size and Forecast
      • 2.1.6.2.1 By End User
  • 2.1.7 Japan
    • 2.1.7.1 Test Volume
    • 2.1.7.2 Market Size and Forecast
      • 2.1.7.2.1 By End User
  • 2.1.8 India
    • 2.1.8.1 Test Volume
    • 2.1.8.2 Market Size and Forecast
      • 2.1.8.2.1 By End User
  • 2.1.9 Australia
    • 2.1.9.1 Test Volume
    • 2.1.9.2 Market Size and Forecast
      • 2.1.9.2.1 By End User
  • 2.1.10 South Korea
    • 2.1.10.1 Test Volume
    • 2.1.10.2 Market Size and Forecast
      • 2.1.10.2.1 By End User
  • 2.1.11 Singapore
    • 2.1.11.1 Test Volume
    • 2.1.11.2 Market Size and Forecast
      • 2.1.11.2.1 By End User
  • 2.1.12 Rest-of-Asia-Pacific
    • 2.1.12.1 Test Volume
    • 2.1.12.2 Market Size and Forecast
      • 2.1.12.2.1 By End User

3 Markets - Competitive Benchmarking & Company Profiles

• 3.1 Company Profiles
  • 3.1.1 Sysmex Corporation
    • 3.1.1.1 Overview
    • 3.1.1.2 Top Products
    • 3.1.1.3 Top Competitors
    • 3.1.1.4 Key Personnel
    • 3.1.1.5 Analyst View

4 Research Methodology

• 4.1 Data Sources
  • 4.1.1 Primary Data Sources
  • 4.1.2 Secondary Data Sources
  • 4.1.3 Data Triangulation
• 4.2 Market Estimation and Forecast

List of Figures

• Figure 1: Asia-Pacific Liquid Biopsy Market, $Million, 2024, 2028, and 2033
• Figure 2: Key Events to Keep Track of in the Liquid Biopsy Market
• Figure 3: Impact of COVID-19 on Liquid Biopsy Market
• Figure 4: Patent Published (by Country), January 2021-May 2024
• Figure 5: Number of Liquid Biopsy Patents (by Year), January 2021-May 2024
• Figure 6: Financing Analysis (by Latest Deal Amount), $Million, FY2023-2024
• Figure 7: Asia-Pacific Liquid Biopsy Market Scenario, 2023
• Figure 8: Frequently Used Technology in Liquid Biopsy
• Figure 9: Most Important Factors for Adoption of NGS-Based Liquid Biopsy
• Figure 10: Treatment Guidelines for Treatment of Cancer Patients
• Figure 11: Major Challenges Faced While Performing Liquid Biopsy
• Figure 12: Average Cost of Technologies for the Liquid Biopsy Market (N=30 )
• Figure 13: Cost Difference Across Different End Users for the Liquid Biopsy Market
• Figure 14: Key Factors for Determining Reimbursement Possibility for the Liquid Biopsy Market
• Figure 15: Estimated Cancer Incidence in 2020 and 2040
• Figure 16: Estimated New Cancer Cases (2022-2045): Both Sexes, Ages 0-85
• Figure 17: Upsurge in Research Publications in Liquid Biopsy, 2015-2023
• Figure 18: Comparison of Liquid Biopsy vs. Tissue Biopsy
• Figure 19: Asia-Pacific Liquid Biopsy Market, Test Volume, Thousand, 2023-2033
• Figure 20: Asia-Pacific Liquid Biopsy Market, $Million, 2023-2033
• Figure 21: China Liquid Biopsy Market, Test Volume, Thousand, 2023-2033
• Figure 22: China Liquid Biopsy Market, $Million, 2023-2033
• Figure 23: Japan Liquid Biopsy Market, Test Volume, Thousand, 2023-2033
• Figure 24: Japan Liquid Biopsy Market, $Million, 2023-2033
• Figure 25: India Liquid Biopsy Market, Test Volume, Thousand, 2023-2033
• Figure 26: India Liquid Biopsy Market, $Million, 2023-2033
• Figure 27: Australia Liquid Biopsy Market, Test Volume, Thousand, 2023-2033
• Figure 28: Australia Liquid Biopsy Market, $Million, 2023-2033
• Figure 29: South Korea Liquid Biopsy Market, Test Volume, Thousand, 2023-2033
• Figure 30: South Korea Liquid Biopsy Market, $Million, 2023-2033
• Figure 31: Singapore Liquid Biopsy Market, Test Volume, Thousand, 2023-2033
• Figure 32: Singapore Liquid Biopsy Market, $Million, 2023-2033
• Figure 33: Rest-of-Asia-Pacific Liquid Biopsy Market, Test Volume, Thousand, 2023-2033
• Figure 34: Rest-of-Asia-Pacific Liquid Biopsy Market, $Million, 2023-2033
• Figure 35: Data Triangulation
• Figure 36: Top-Down and Bottom-Up Approach
• Figure 37: Assumptions and Limitations

List of Tables

• Table 1: Market Snapshot
• Table 2: Asia-Pacific Liquid Biopsy Market, Market Opportunities
• Table 3: Product Launches, January 2021-April 2024
• Table 4: Some of the Strategic Funding, January 2022-April 2024
• Table 5: Launched Liquid Biopsy Tests from Players in the Liquid Biopsy Market
• Table 6: Reimbursement Scenario for Key Players' Offerings in the Liquid Biopsy Market
• Table 7: Liquid Biopsy Market: Key Players Patent Portfolio
• Table 8: Liquid Biopsy Product Mapping Analysis (by Technology)
• Table 9: Liquid Biopsy Product Mapping Analysis (by Sample)
• Table 10: Liquid Biopsy Product Mapping Analysis (by Circulating Biomarker)
• Table 11: Liquid Biopsy Product Mapping Analysis (by Clinical Application)
• Table 12: Government Initiatives for Liquid Biopsies
• Table 13: Impact Analysis of Market Navigating Factors, 2023-2033
• Table 14: Liquid Biopsy Market (by Region), $Million, 2023-2033
• Table 15: Asia-Pacific Liquid Biopsy Market (by End User), $Million, 2023-2033
• Table 16: China Liquid Biopsy Market (by End User), $Million, 2023-2033
• Table 17: Japan Liquid Biopsy Market (by End User), $Million, 2023-2033
• Table 18: India Liquid Biopsy Market (by End User), $Million, 2023-2033
• Table 19: Australia Liquid Biopsy Market (by End User), $Million, 2023-2033
• Table 20: South Korea Liquid Biopsy Market (by End User), $Million, 2023-2033
• Table 21: Singapore Liquid Biopsy Market (by End User), $Million, 2023-2033
• Table 22: Rest-of-Asia-Pacific Liquid Biopsy Market (by End User), $Million, 2023-2033